18.07.2017 20:32:00
|
ANGIODYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In AngioDynamics, Inc. To Contact The Firm
NEW YORK, July 18, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AngioDynamics, Inc. ("AngioDynamics" or the "Company") (NASDAQ: ANGO).
The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, after market on July 17, 2017, the Company filed a Form 8-K with the Securities and Exchange Commission disclosing, among other things, that its former independent registered public accounting firm has "determined that there was a material weakness in the Company's internal control over financial reporting as of May 31, 2016 because the Company did not design and maintain effective internal controls over the accounting for the annual goodwill impairment test."
On this news, the Company's share price declined, causing harm to investors.
If you invested in AngioDynamics stock or options and would like to discuss your legal rights, click here:www.faruqilaw.com/ANGO. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.
CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View original content with multimedia:http://www.prnewswire.com/news-releases/angiodynamics-investor-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-exceeding-50000-investing-in-angiodynamics-inc-to-contact-the-firm-300490141.html
SOURCE Faruqi & Faruqi, LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AngioDynamics Inc.mehr Nachrichten
20.11.24 |
NASDAQ Composite Index-Titel AngioDynamics-Aktie: So viel Verlust wäre bei einem Investment in AngioDynamics von vor einem Jahr angefallen (finanzen.at) | |
13.11.24 |
NASDAQ Composite Index-Papier AngioDynamics-Aktie: So viel hätte eine Investition in AngioDynamics von vor 10 Jahren gekostet (finanzen.at) | |
12.11.24 |
Börse New York: NASDAQ Composite präsentiert sich schlussendlich schwächer (finanzen.at) | |
12.11.24 |
Dienstagshandel in New York: NASDAQ Composite liegt am Dienstagnachmittag im Minus (finanzen.at) | |
12.11.24 |
Verluste in New York: NASDAQ Composite verliert am Mittag (finanzen.at) | |
12.11.24 |
Aufschläge in New York: NASDAQ Composite startet mit Gewinnen (finanzen.at) | |
11.11.24 |
Handel in New York: NASDAQ Composite beendet den Montagshandel in der Gewinnzone (finanzen.at) | |
11.11.24 |
Zurückhaltung in New York: NASDAQ Composite präsentiert sich nachmittags schwächer (finanzen.at) |